Targeted radioactive antibody therapy combined with new drug combinations for AML
Combining Targeted RIT and Synergistic Novel Agent-Renewal
['FUNDING_R37'] · FRED HUTCHINSON CANCER CENTER · NIH-10978055
This project uses antibodies carrying tiny radioactive payloads together with new drugs to treat people with acute myeloid leukemia (AML), especially those who cannot tolerate intense chemotherapy or a transplant.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10978055 on ClinicalTrials.gov |
What this research studies
This work aims to deliver radiation directly to leukemia cells by linking radioactive atoms to antibodies that recognize AML cells, so most healthy organs receive less exposure. Researchers are comparing different isotopes including 90Y, 131I, and the higher-energy alpha emitter astatine-211 to find safer, more powerful options. They plan to combine this targeted radiation with synergistic new drugs to kill leukemia cells and reduce the chance of resistance. The program includes lab and preclinical development with the goal of moving toward treatments that patients with AML could receive in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates would be adults with AML who are unfit for intensive chemotherapy, lack a matched donor for transplant, or have relapsed/refractory disease.
Not a fit: Patients with other cancer types, those whose AML is well controlled by standard treatments, or people unable to receive radioactive therapies would likely not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could more effectively kill leukemia cells while reducing the toxic side effects of whole-body radiation and intensive chemotherapy.
How similar studies have performed: Previous work using anti-CD45 radioimmunotherapy with 90Y and 131I has shown promise in clinical and translational studies, while use of alpha-emitters like 211At is newer and less tested but potentially more potent.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OROZCO, JOHNNIE JOSE — FRED HUTCHINSON CANCER CENTER
- Study coordinator: OROZCO, JOHNNIE JOSE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.